Philippe L Pereira1, Kristina Krüger2, Ernst Hohenstein2, Florian Welke3, Christof Sommer4, Friedegund Meier5, Thomas Eigentler6, Claus Garbe6. 1. Clinic for Radiology, Minimally-Invasive Therapies and Nuclearmedicine, SLK-Kliniken GmbH, Heilbronn, Am Gesundbrunnen 20-26, 74078, Heilbronn, Germany. philippe.pereira@slk-kliniken.de. 2. Clinic for Radiology, Minimally-Invasive Therapies and Nuclearmedicine, SLK-Kliniken GmbH, Heilbronn, Am Gesundbrunnen 20-26, 74078, Heilbronn, Germany. 3. Institute for Diagnostic and Interventional Radiology, Klinikum Ludwigsburg, Posilipostraße 4, 71640, Ludwigsburg, Germany. 4. Clinic for Diagnostic and Interventional Radiology, Ruprecht Karls University of Heidelberg, Im Neuenheimer Feld 110, 69120, Heidelberg, Germany. 5. Clinic for Dermato-Oncology, Universitätsklinikum Carl Gustav Carus, Fiedlerstraße 19, 01307, Dresden, Germany. 6. Clinic für Dermato-Oncology, Eberhard-Karls University, Liebermeisterstraße 25, 72076, Tübingen, Germany.
Abstract
OBJECTIVES: To study feasibility and validity of a new software application for intraprocedural assessment of perfusion during chemoembolisation of melanoma metastases. METHODOLOGY: In a prospective phase-II trial, ten melanoma patients with liver-only metastases underwentchemoembolisation with doxorubicin-eluting beads (DEBDOX-TACE). Tumour perfusion was evaluated immediately before and after treatment at cone beam computer tomography (CBCT) using a new software application. For control and comparison, patients underwent perfusion measurement via contrast-enhanced multidetector CT (MDCT) before and after treatment. RESULTS:CBCT showed 94.7 % reduction in perfusion in metastases after DEBDOX-TACE, whereas MDCT showed 96.8 %. Reduction in perfusion after treatment was statistically significant (p < 0.01) for both methods. The additional time needed for data acquisition during treatment was 5 min per case or less; the post-processing data analysis was 10 min or less. Perfusion imaging was associated with additional contrast agent and patient exposure to radiation (dose-length product [DLP]): 18 ml and 394 mGy*cm in CBCT and 100 ml and 446 mGy*cm in MDCT, respectively. CONCLUSIONS:Reduction in perfusion of melanoma metastases after DEBDOX-TACE can be reliably assessed during the intervention via perfusion software at CBCT. Data acquisition and analysis require additional time but can be easily performed during the treatment. KEY POINTS: • Tumour perfusion of melanoma metastases can be assessed at cone beam CT. • The software shows a significant decrease of tumour perfusion after DEBDOX-TACE. • Data acquisition and analysis require an acceptable additional time during the procedure. • CBCT requires less radiation exposure and contrast for perfusion study than MSCT. • This software can monitor the course of DEBDOX-TACE in melanoma metastases.
RCT Entities:
OBJECTIVES: To study feasibility and validity of a new software application for intraprocedural assessment of perfusion during chemoembolisation of melanoma metastases. METHODOLOGY: In a prospective phase-II trial, ten melanomapatients with liver-only metastases underwent chemoembolisation with doxorubicin-eluting beads (DEBDOX-TACE). Tumour perfusion was evaluated immediately before and after treatment at cone beam computer tomography (CBCT) using a new software application. For control and comparison, patients underwent perfusion measurement via contrast-enhanced multidetector CT (MDCT) before and after treatment. RESULTS: CBCT showed 94.7 % reduction in perfusion in metastases after DEBDOX-TACE, whereas MDCT showed 96.8 %. Reduction in perfusion after treatment was statistically significant (p < 0.01) for both methods. The additional time needed for data acquisition during treatment was 5 min per case or less; the post-processing data analysis was 10 min or less. Perfusion imaging was associated with additional contrast agent and patient exposure to radiation (dose-length product [DLP]): 18 ml and 394 mGy*cm in CBCT and 100 ml and 446 mGy*cm in MDCT, respectively. CONCLUSIONS: Reduction in perfusion of melanoma metastases after DEBDOX-TACE can be reliably assessed during the intervention via perfusion software at CBCT. Data acquisition and analysis require additional time but can be easily performed during the treatment. KEY POINTS: • Tumour perfusion of melanoma metastases can be assessed at cone beam CT. • The software shows a significant decrease of tumour perfusion after DEBDOX-TACE. • Data acquisition and analysis require an acceptable additional time during the procedure. • CBCT requires less radiation exposure and contrast for perfusion study than MSCT. • This software can monitor the course of DEBDOX-TACE in melanoma metastases.
Authors: Michael J Wallace; Ravi Murthy; Paresh P Kamat; Teri Moore; Sujaya H Rao; Joe Ensor; Sanjay Gupta; Kamran Ahrar; David C Madoff; Stephen E McRae; Marshall E Hicks Journal: J Vasc Interv Radiol Date: 2007-12 Impact factor: 3.464
Authors: A S Ahmed; M Zellerhoff; C M Strother; K A Pulfer; T Redel; Y Deuerling-Zheng; K Royalty; D Consigny; D B Niemann Journal: AJNR Am J Neuroradiol Date: 2009-03-19 Impact factor: 3.825
Authors: Daniel Spira; Maximilian Schulze; Alexander Sauter; Harald Brodoefel; Klaus Brechtel; Claus Claussen; Marius Horger Journal: Eur J Radiol Date: 2011-05-02 Impact factor: 3.528
Authors: Bora Peynircioğlu; Mustafa Hızal; Barbaros Çil; Yu Deuerling-Zheng; Martin Von Roden; Tuncay Hazırolan; Deniz Akata; Mustafa Özmen; Ferhun Balkancı Journal: Diagn Interv Radiol Date: 2015 Jan-Feb Impact factor: 2.630
Authors: Johannes Lammer; Katarina Malagari; Thomas Vogl; Frank Pilleul; Alban Denys; Anthony Watkinson; Michael Pitton; Geraldine Sergent; Thomas Pfammatter; Sylvain Terraz; Yves Benhamou; Yves Avajon; Thomas Gruenberger; Maria Pomoni; Herbert Langenberger; Marcus Schuchmann; Jerome Dumortier; Christian Mueller; Patrick Chevallier; Riccardo Lencioni Journal: Cardiovasc Intervent Radiol Date: 2009-11-12 Impact factor: 2.740
Authors: Martina Gurgitano; Giulia Signorelli; Giovanni Maria Rodà; Alessandro Liguori; Marco Pandolfi; Giuseppe Granata; Antonio Arrichiello; Anna Maria Ierardi; Aldo Paolucci; Gianpaolo Carrafiello Journal: Acta Biomed Date: 2020-09-23